Wasik, AM; Gandy, MN; McIldowie, M; Holder, MJ; Chamba, A; Challa, A; Lewis, KD; Young, SP; Scheel-Toellner, D; Dyer, MJ; Barnes, NM; Piggott, MJ; Gordon, J. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine (‘ecstasy’) through iterative chemical redesign: mechanisms and pathways to cell death Invest. New Drugs, 1 Aug 2012, 30 (4), 1471-1483. 575 kB. https://doi.org/10.1007/s10637-011-9730-5 #8
Gandy, MN; Mclldowie, M; Lewis, K; Wasik, AM; Salomonczyk, D; Wagg, K; Millar, ZA; Tindiglia, D; Huot, P; Johnston, T; Thiele, S; Nguyen, B; Barnes, NM; Brotchie, JM; Martin-Iverson, MT. Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt’s lymphoma cytotoxicity Med. Chem. Commun., 1 Oct 2010, 1 (4), 287–293. 177 kB. https://doi.org/10.1039/c0md00108b #11p
N-Benzyl-3,4-methylenedioxyamphetamine · N-Benzyl-MDA · MDBZ
2-Me-Phenyl-MDMA · α-(2-Methylphenyl)-N-methyl-3,4-methylenedioxyphenethylamine
3-Me-Phenyl-MDMA · α-(3-Methylphenyl)-N-methyl-3,4-methylenedioxyphenethylamine
4-Me-Phenyl-MDMA · α-(4-Methylphenyl)-N-methyl-3,4-methylenedioxyphenethylamine